Search

Your search keyword '"Vigano R"' showing total 163 results
Start Over Author "Vigano R"
163 results on '"Vigano R"'

1. Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation

Author

Cortesi, P, Vigano, R, Conti, S, Lenci, I, Volpes, R, Martini, S, Angelico, M, Fung, J, Buti, M, Coilly, A, Durand, F, Fondevila, C, Lebray, P, Nevens, F, Polak, W, Rizzetto, M, Zoulim, F, Perricone, G, Berenguer, M, Mantovani, L, Duvoux, C, Belli, L, Cortesi P. A., Vigano R., Conti S., Lenci I., Volpes R., Martini S., Angelico M., Fung J., Buti M., Coilly A., Durand F., Fondevila C., Lebray P., Nevens F., Polak W. G., Rizzetto M., Zoulim F., Perricone G., Berenguer M., Mantovani L. G., Duvoux C., Belli L. S., Cortesi, P, Vigano, R, Conti, S, Lenci, I, Volpes, R, Martini, S, Angelico, M, Fung, J, Buti, M, Coilly, A, Durand, F, Fondevila, C, Lebray, P, Nevens, F, Polak, W, Rizzetto, M, Zoulim, F, Perricone, G, Berenguer, M, Mantovani, L, Duvoux, C, Belli, L, Cortesi P. A., Vigano R., Conti S., Lenci I., Volpes R., Martini S., Angelico M., Fung J., Buti M., Coilly A., Durand F., Fondevila C., Lebray P., Nevens F., Polak W. G., Rizzetto M., Zoulim F., Perricone G., Berenguer M., Mantovani L. G., Duvoux C., and Belli L. S.

Abstract

The European Liver and Intestine Transplant Association, ELITA, promoted a Consensus Conference involving 20 experts across the world which generated updated guidelines on HBV prophylaxis in liver transplant candidates and recipients. This study explores the economic impact associated with the implementation of the new ELITA guidelines. To this aim, a condition-specific cohort simulation model has been developed to compare new and historical prophylaxis, including only pharmaceutical cost and using the European perspective. The target population simulated in the model included both prevalent and incident cases, and consisted of 6,133 patients after the first year, that increased to 7,442 and 8,743 patents after 5 and 10 years from its implementation. The ELITA protocols allowed a cost saving of around € 235.65 million after 5 years and € 540.73 million after 10 years; which was mainly due to early HIBG withdrawal either after the first 4 weeks or after the first year post Liver Transplantation (LT) depending on the virological risk at transplantation. Results were confirmed by sensitivity analyses. The money saved by the implementation of the ELITA guidelines would allow healthcare decision makers and budget holders to understand where costs could be reduced and resources re-allocated to different needs.

Published
2023

2. Similar survival but higher and delayed hepatocellular carcinoma recurrence in HIV-positive compared to negative cirrhotics undergoing liver transplantation

Author

Rossotti, R, Merli, M, Mazzarelli, C, De Carlis, R, Travi, G, Vecchi, M, Vigano, R, Lauterio, A, Raimondi, A, Belli, L, De Carlis, L, Puoti, M, Rossotti R., Merli M., Mazzarelli C., De Carlis R. M., Travi G., Vecchi M., Vigano R., Lauterio A., Raimondi A., Belli L. S., De Carlis L. G., Puoti M., Rossotti, R, Merli, M, Mazzarelli, C, De Carlis, R, Travi, G, Vecchi, M, Vigano, R, Lauterio, A, Raimondi, A, Belli, L, De Carlis, L, Puoti, M, Rossotti R., Merli M., Mazzarelli C., De Carlis R. M., Travi G., Vecchi M., Vigano R., Lauterio A., Raimondi A., Belli L. S., De Carlis L. G., and Puoti M.

Abstract

Background: Liver transplantation (LT) represents the best therapeutic option for hepatocellular carcinoma (HCC) and end-stage liver disease (ESLD). Although HIV infection does not seem to lower survival rates, HCV and HCC recurrence appear more harmful. Aims: To compare the overall survival after LT; evaluate the impact of anti-HCV direct-acting agents (DAA); assess the rate of HCC recurrence in HIV-positive and negative patients. Methods: Subjects with HCV/HBV infection who underwent LT for HCC or ESLD from 2012 to 2019 were retrospectively evaluated. Results: Study population included 299 individuals, 31 (10.4%) were HIV-positive. Overall mortality was similar (16.1% versus 19.0%, p = 0.695). HCC recurrence was observed in 6 HIV-positive (19.4%) and in 17 negative subjects (6.3%, p = 0.022). Time to relapse was 831 days in HIV-positive and 315 days in negative patients (p = 0.046). Cox model found a significant role for HIV in univariate analysis but, after adjusting for variables, extra-hepatic tumor was the only factor associated to recurrence (aHR 56.379, p < 0.001). Conclusions: Post-LT survival improved after DAA availability and HIV has no impact on mortality. A higher and delayed rate of HCC recurrence was observed in co-infected individuals: surveillance protocols should be strengthened along time in this population.

Published
2023

3. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

Author

Caraceni, P, Tufoni, M, Zaccherini, G, Riggio, O, Angeli, P, Alessandria, C, Neri, S, Foschi, F, Levantesi, F, Airoldi, A, Simone, L, Svegliati-Baroni, G, Fagiuoli, S, Laffi, G, Cozzolongo, R, Di Marco, V, Sangiovanni, V, Morisco, F, Toniutto, P, Gasbarrini, A, De Marco, R, Piano, S, Nardelli, S, Elia, C, Roncadori, A, Baldassarre, M, Bernardi, M, Domenicali, M, Giannone, F, Antognoli, A, Merli, M, Pasquale, C, Gioia, S, Fasolato, S, Sticca, A, Campion, D, Risso, A, Saracco, G, Prestianni, L, Fidone, F, Maiorca, D, Rizzotto, A, Cappa, F, Lanzi, A, Neri, E, Visani, A, Mastroianni, A, Perricone, G, Alberti, A, Cesarini, L, Mazzarelli, C, Vangeli, M, Vigano, R, Marzioni, M, Capretti, F, Kostandini, A, Magini, G, Colpani, M, Gabbani, T, Marsico, M, Zappimbulso, M, Petruzzi, J, Calvaruso, V, Parrella, G, Caporaso, N, Auriemma, F, Guarino, M, Pugliese, F, Tortora, A, Leo, P, Angelico, M, De Leonardis, F, Pecchioli, A, Rossi, P, Raimondo, G, Cacciola, I, Elia, G, Negri, E, Dallio, M, Loguercio, C, Federico, A, Conte, D, Massironi, S, Natascia Celli, G, Rendina, M, Bringiotti, R, Castellaneta, N, Salerno, F, Boccia, S, Guarisco, R, Galioto, A, Cavallin, M, Andrealli, A, Caraceni P., Tufoni M., Zaccherini G., Riggio O., Angeli P., Alessandria C., Neri S., Foschi F. G., Levantesi F., Airoldi A., Simone L., Svegliati-Baroni G., Fagiuoli S., Laffi G., Cozzolongo R., Di Marco V., Sangiovanni V., Morisco F., Toniutto P., Gasbarrini A., De Marco R., Piano S., Nardelli S., Elia C., Roncadori A., Baldassarre M., Bernardi M., Domenicali M., Giannone F. A., Antognoli A., Merli M., Pasquale C., Gioia S., Fasolato S., Sticca A., Campion D., Risso A., Saracco G. M., Prestianni L., Fidone F., Maiorca D., Rizzotto A., Cappa F. M., Lanzi A., Neri E., Visani A., Mastroianni A., Perricone G., Alberti A. B., Cesarini L., Mazzarelli C., Vangeli M., Vigano R., Marzioni M., Capretti F., Kostandini A., Magini G., Colpani M., Gabbani T., Marsico M., Zappimbulso M., Petruzzi J., Calvaruso V., Parrella G., Caporaso N., Auriemma F., Guarino M., Pugliese F., Tortora A., Leo P., Angelico M., De Leonardis F., Pecchioli A., Rossi P., Raimondo G., Cacciola I., Elia G., Negri E., Dallio M., Loguercio C., Federico A., Conte D., Massironi S., Natascia Celli G. B., Rendina M., Bringiotti R., Castellaneta N. M., Salerno F., Boccia S., Guarisco R., Galioto A., Cavallin M., Andrealli A., Caraceni, P, Tufoni, M, Zaccherini, G, Riggio, O, Angeli, P, Alessandria, C, Neri, S, Foschi, F, Levantesi, F, Airoldi, A, Simone, L, Svegliati-Baroni, G, Fagiuoli, S, Laffi, G, Cozzolongo, R, Di Marco, V, Sangiovanni, V, Morisco, F, Toniutto, P, Gasbarrini, A, De Marco, R, Piano, S, Nardelli, S, Elia, C, Roncadori, A, Baldassarre, M, Bernardi, M, Domenicali, M, Giannone, F, Antognoli, A, Merli, M, Pasquale, C, Gioia, S, Fasolato, S, Sticca, A, Campion, D, Risso, A, Saracco, G, Prestianni, L, Fidone, F, Maiorca, D, Rizzotto, A, Cappa, F, Lanzi, A, Neri, E, Visani, A, Mastroianni, A, Perricone, G, Alberti, A, Cesarini, L, Mazzarelli, C, Vangeli, M, Vigano, R, Marzioni, M, Capretti, F, Kostandini, A, Magini, G, Colpani, M, Gabbani, T, Marsico, M, Zappimbulso, M, Petruzzi, J, Calvaruso, V, Parrella, G, Caporaso, N, Auriemma, F, Guarino, M, Pugliese, F, Tortora, A, Leo, P, Angelico, M, De Leonardis, F, Pecchioli, A, Rossi, P, Raimondo, G, Cacciola, I, Elia, G, Negri, E, Dallio, M, Loguercio, C, Federico, A, Conte, D, Massironi, S, Natascia Celli, G, Rendina, M, Bringiotti, R, Castellaneta, N, Salerno, F, Boccia, S, Guarisco, R, Galioto, A, Cavallin, M, Andrealli, A, Caraceni P., Tufoni M., Zaccherini G., Riggio O., Angeli P., Alessandria C., Neri S., Foschi F. G., Levantesi F., Airoldi A., Simone L., Svegliati-Baroni G., Fagiuoli S., Laffi G., Cozzolongo R., Di Marco V., Sangiovanni V., Morisco F., Toniutto P., Gasbarrini A., De Marco R., Piano S., Nardelli S., Elia C., Roncadori A., Baldassarre M., Bernardi M., Domenicali M., Giannone F. A., Antognoli A., Merli M., Pasquale C., Gioia S., Fasolato S., Sticca A., Campion D., Risso A., Saracco G. M., Prestianni L., Fidone F., Maiorca D., Rizzotto A., Cappa F. M., Lanzi A., Neri E., Visani A., Mastroianni A., Perricone G., Alberti A. B., Cesarini L., Mazzarelli C., Vangeli M., Vigano R., Marzioni M., Capretti F., Kostandini A., Magini G., Colpani M., Gabbani T., Marsico M., Zappimbulso M., Petruzzi J., Calvaruso V., Parrella G., Caporaso N., Auriemma F., Guarino M., Pugliese F., Tortora A., Leo P., Angelico M., De Leonardis F., Pecchioli A., Rossi P., Raimondo G., Cacciola I., Elia G., Negri E., Dallio M., Loguercio C., Federico A., Conte D., Massironi S., Natascia Celli G. B., Rendina M., Bringiotti R., Castellaneta N. M., Salerno F., Boccia S., Guarisco R., Galioto A., Cavallin M., and Andrealli A.

Abstract

Background & Aims: The ANSWER study reported that long-term albumin administration in patients with cirrhosis and uncomplicated ascites improves survival. During treatment, serum albumin increased within a month and remained stable thereafter. In this post hoc analysis, we aimed to determine whether on-treatment serum albumin levels could guide therapy. Methods: Logistic regression was used to assess the association between baseline serum albumin and mortality, as well as to determine on-treatment factors associated with mortality and to predict the achievement of a given on-treatment serum albumin level. Survival was assessed by Kaplan-Meier estimates and second-order polynomial regression. Patients whose on-treatment serum albumin remained below normal were compared with a subset of patients from the control arm matched by principal score. Results: Baseline serum albumin was closely associated with 18-month mortality in untreated patients; albumin treatment almost effaced this relationship. On-treatment serum albumin and MELD-Na at month 1 were the sole independent variables associated with mortality. Second-order polynomial regression revealed that survival improved in parallel with increased 1-month on-treatment serum albumin. Kaplan-Meier estimations showed that any value of 1-month on-treatment serum albumin (0.1 g/dl intervals) in the range 2.5–4.5 g/dl discriminated patient survival. In the normal range of serum albumin, the best discriminant value was 4.0 g/dl. Compared to untreated patients, survival even improved in patients whose on-treatment serum albumin remained below normal. Conclusion: Baseline serum albumin per se should not guide the decision to start albumin therapy. Conversely, 1-month on-treatment serum albumin levels are strongly associated with outcomes and could guide the use of albumin – 4.0 g/dl being the target threshold. However, even patients whose serum albumin remains below normal benefit from long-term albumin administration. Lay

Published
2021

5. Liver transplantation for primary sclerosing cholangitis

Author

Pasulo, L, Mazzarelli, C, Iegri, C, Mangia, G, Leonardi, F, D'antiga, L, Colledan, M, Belli, L, Fagiuoli, S, Mauri, M, Vigano, R, Pasulo, L, Mazzarelli, C, Iegri, C, Mangia, G, Leonardi, F, D'Antiga, L, Colledan, M, Belli, L, Fagiuoli, S, Mauri, M, and Vigano, R

Subjects
PSC, IBD, liver transplant
Published
2021

10. Liver transplant candidates and SARS-CoV-2 infection: Results from an Italian multicenter cohort

Author

Perricone, G., primary, Vigano, R., additional, Mazzarelli, C., additional, Travi, G., additional, Pasulo, L., additional, Invernizzi, F., additional, Morelli, M.C., additional, Patrono, D., additional, Sandro, S. Di, additional, De Simone, P., additional, Facchetti, R., additional, Angrisani, D., additional, De Nicola, S., additional, Airoldi, A., additional, Vangeli, M., additional, and Belli, e L.S., additional

Published
2021
Full Text
View/download PDF

12. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis

Author

Vukotic, R, Conti, F, Fagiuoli, S, Morelli, M, Pasulo, L, Colpani, M, Foschi, F, Berardi, S, Pianta, P, Mangano, M, Donato, M, Malinverno, F, Monico, S, Tame, M, Mazzella, G, Belli, L, Vigano, R, Carrai, P, Burra, P, Russo, F, Lenci, I, Toniutto, P, Merli, M, Loiacono, L, Iemmolo, R, Degli Antoni, A, Romano, A, Picciotto, A, Rendina, M, Andreone, P, Vukotic R., Conti F., Fagiuoli S., Morelli M. C., Pasulo L., Colpani M., Foschi F. G., Berardi S., Pianta P., Mangano M., Donato M. F., Malinverno F., Monico S., Tame M., Mazzella G., Belli L. S., Vigano R., Carrai P., Burra P., Russo F. P., Lenci I., Toniutto P., Merli M., Loiacono L., Iemmolo R., Degli Antoni A. M., Romano A., Picciotto A., Rendina M., Andreone P., Vukotic, R, Conti, F, Fagiuoli, S, Morelli, M, Pasulo, L, Colpani, M, Foschi, F, Berardi, S, Pianta, P, Mangano, M, Donato, M, Malinverno, F, Monico, S, Tame, M, Mazzella, G, Belli, L, Vigano, R, Carrai, P, Burra, P, Russo, F, Lenci, I, Toniutto, P, Merli, M, Loiacono, L, Iemmolo, R, Degli Antoni, A, Romano, A, Picciotto, A, Rendina, M, Andreone, P, Vukotic R., Conti F., Fagiuoli S., Morelli M. C., Pasulo L., Colpani M., Foschi F. G., Berardi S., Pianta P., Mangano M., Donato M. F., Malinverno F., Monico S., Tame M., Mazzella G., Belli L. S., Vigano R., Carrai P., Burra P., Russo F. P., Lenci I., Toniutto P., Merli M., Loiacono L., Iemmolo R., Degli Antoni A. M., Romano A., Picciotto A., Rendina M., and Andreone P.

Abstract

Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three patients with cirrhosis (n=52) or fibrosing cholestatic hepatitis (FCH, n=21) received 24-week sofosbuvir with ribavirin±pegylated interferon or interferon-free sofosbuvir-based regimen with daclatasvir/simeprevir+ribavirin. The patients were observed for a median time of 103 (82-112) weeks. Twelve of 73 (16.4%) died (10 non-FCH, 2 FCH) and two underwent re-LT. Sustained virological response was achieved in 46 of 66 (69.7%): 31 of 47 (66%) non-FCH and 15 of 19 (79%) FCH patients. All relapsers were successfully retreated. Comparing the data of baseline with last follow-up, MELD and Child-Turcotte-Pugh scores improved both in non-FCH (15.3±6.5 vs 10.5±3.8, P<.0001 and 8.4±2.1 vs 5.7±1.3, P<.0001, respectively) and FCH (17.3±5.9 vs 10.1±2.8, P=.001 and 8.2±1.6 vs 5.5±1, P=.001, respectively). Short-treatment mortality was higher in patients with baseline MELD≥25 than in those with MELD<25 (42.9% vs 4.8%, P=.011). Long-term mortality was 53.3% among patients with baseline MELD≥20 and 7.5% among those with MELD<20 (P<.0001). Among deceased patients 75% were Child-Turcotte-Pugh class C at baseline, while among survivors 83.9% were class A or B (P<.0001). Direct acting antivirals-based treatments for severe post-transplant hepatitis C recurrence, comprising fibrosing cholestatic hepatitis, significantly improve liver function, even without viral clearance and permit an excellent long-term survival. The setting of severe HCV recurrence may require the identification of “too-sick-to-treat patients” to avoid futile treatments.

Published
2017

14. PRE-EMPTIVE POST-TRANSPLANT HCV TREATMENT WITH IFN-FREE DAA: PRELIMINARY RESULTS FROM A PILOT STUDY

Author

Pasulo, L, Di Benedetto, C, Mazzarelli, C, Iegri, C, Mangiola, F, Perricone, G, Vigano, R, Colledan, M, De Carlis, L, Corti, A, Mazza, E, De Gasperi, A, Marchesi, M, Donato, F, Fagiuoli, S, Belli, L, Pasulo L, Di Benedetto C, Mazzarelli C, Iegri C, Mangiola F, Perricone G, Vigano R, Colledan M, De Carlis L, Corti A, Mazza E, De Gasperi A, Marchesi M, Donato F, Fagiuoli S, Belli L, Pasulo, L, Di Benedetto, C, Mazzarelli, C, Iegri, C, Mangiola, F, Perricone, G, Vigano, R, Colledan, M, De Carlis, L, Corti, A, Mazza, E, De Gasperi, A, Marchesi, M, Donato, F, Fagiuoli, S, Belli, L, Pasulo L, Di Benedetto C, Mazzarelli C, Iegri C, Mangiola F, Perricone G, Vigano R, Colledan M, De Carlis L, Corti A, Mazza E, De Gasperi A, Marchesi M, Donato F, Fagiuoli S, and Belli L

Published
2016

21. GENOTYPE 2 AND 3 RECCURENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EXCELLENT RESULTS WITH SUBOPTIMAL DOSES OF ANTIVIRAL THERAPY

Author

Vigano, R, Ponziani, F, Belli, L, Vangeli, M, Pinzello, G, Gasbarrini, A, Pasulo, L, De Martin, E, Burra, R, Pompili, M, Colledan, M, Cillo, U, Fagiuoli, S, Vigano R, Ponziani FR, Belli LS, Vangeli M, Pinzello G, Gasbarrini A, Pasulo L, De Martin E, Burra R, Pompili M, Colledan M, Cillo U, Fagiuoli S, Vigano, R, Ponziani, F, Belli, L, Vangeli, M, Pinzello, G, Gasbarrini, A, Pasulo, L, De Martin, E, Burra, R, Pompili, M, Colledan, M, Cillo, U, Fagiuoli, S, Vigano R, Ponziani FR, Belli LS, Vangeli M, Pinzello G, Gasbarrini A, Pasulo L, De Martin E, Burra R, Pompili M, Colledan M, Cillo U, and Fagiuoli S

Published
2009

22. Genotype 2 and 3 Reccurent Hepatitis C after Liver Transplantation: Excellent Results with Suboptimal Doses of Antiviral Therapy

Author

De Martin, E, Vigano, R, Ponziani, F, Pasulo, L, Colledan, M, Pompili, M, Gasbarrini, A, Belli, L, Pinzello, G, Donato, F, Fagiuoli, S, Burra, P, De Martin E, Vigano R, Ponziani FR, Pasulo L, Colledan M, Pompili M, Gasbarrini A, Belli L, Pinzello G, Donato FM, Fagiuoli S, Burra P, De Martin, E, Vigano, R, Ponziani, F, Pasulo, L, Colledan, M, Pompili, M, Gasbarrini, A, Belli, L, Pinzello, G, Donato, F, Fagiuoli, S, Burra, P, De Martin E, Vigano R, Ponziani FR, Pasulo L, Colledan M, Pompili M, Gasbarrini A, Belli L, Pinzello G, Donato FM, Fagiuoli S, and Burra P

Published
2009

23. THE BENEFIT OF ANTIVIRAL THERAPY ON FIBROSIS PROGRESSION DUE TO HCV RECURRENCE AFTER LIVER TRANSPLANTATION (LT): AN ITALIAN MULTICENTER STUDY

Author

De Martin, E, Senzolo, M, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, M, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Merli, M, Villa, E, Russo, F, Boninsegna, S, Cillo, U, Gasbarrini, A, Toniutto, P, Fagiuoli, S, Burra, P, De Martin E, Senzolo M, Ponziani F, Vigano R, Belli LS, Pinzello G, Colledan M, Donato MF, Di Paolo D, Angelico M, Rendina M, Pompili M, Merli M, Villa E, Russo FP, Boninsegna S, Cillo U, Gasbarrini A, Toniutto P, Fagiuoli S, Burra P, De Martin, E, Senzolo, M, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, M, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Merli, M, Villa, E, Russo, F, Boninsegna, S, Cillo, U, Gasbarrini, A, Toniutto, P, Fagiuoli, S, Burra, P, De Martin E, Senzolo M, Ponziani F, Vigano R, Belli LS, Pinzello G, Colledan M, Donato MF, Di Paolo D, Angelico M, Rendina M, Pompili M, Merli M, Villa E, Russo FP, Boninsegna S, Cillo U, Gasbarrini A, Toniutto P, Fagiuoli S, and Burra P

Published
2009

24. GENOTYPE 2 AND 3 RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EXCELLENT RESULTS WITH SUBOPTIMAL DOSES OF ANTIVIRAL THERAPY

Author

Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, De Martin, E, Burra, P, Boninsegna, S, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Fagiuoli, S, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, De Martin E, Burra P, Boninsegna S, Donato F, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, Fagiuoli S, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, De Martin, E, Burra, P, Boninsegna, S, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Fagiuoli, S, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, De Martin E, Burra P, Boninsegna S, Donato F, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, and Fagiuoli S

Published
2009

25. FIBROSIS PROGRESSION AFTER ANTIVIRAL TREATMENT (AT) FOR HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION

Author

De Martin, E, Masier, A, Senzolo, M, Boninsegna, S, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Russo, F, Cillo, U, Fagiuoli, S, Burra, P, De Martin E, Masier A, Senzolo M, Boninsegna S, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, Donato FC, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, Russo FP, Cillo U, Fagiuoli S, Burra P, De Martin, E, Masier, A, Senzolo, M, Boninsegna, S, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Russo, F, Cillo, U, Fagiuoli, S, Burra, P, De Martin E, Masier A, Senzolo M, Boninsegna S, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, Donato FC, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, Russo FP, Cillo U, Fagiuoli S, and Burra P

Published
2009

26. ANTIVIRAL TREATMENT (AT) FOR HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION: THE IMPACT ON FIBROSIS PROGRESSION

Author

De Martin, E, Senzolo, M, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Russo, F, Cillo, U, Fagiuoli, S, De Martin E, Senzolo M, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, Donato F, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, Russo FP, Cillo U, Fagiuoli S, De Martin, E, Senzolo, M, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Russo, F, Cillo, U, Fagiuoli, S, De Martin E, Senzolo M, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, Donato F, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, Russo FP, Cillo U, and Fagiuoli S

Published
2009

27. The Persistence of HCV Replication Is Associated with an Increased Mortality Rate in HCV Recurrent Transplant Patients: Results from the AISF-RECOLT-C Group

Author

Rendina, M., Castellaneta, N. M., Fagiuoli, Stefano, Ponziani, F., Vigano, R., Iemmolo, R. M., Donato, M. F., Toniutto, P., Pasulo, L., Morelli, M. C., Burra, Patrizia, Miglioresi, L., Giannelli, V., Paolo, D. D., Leo, A. D., Rendina, M, Castellaneta, N, Fagiuoli, S, Ponziani, F, Vigano, R, Iemmolo, R, Donato, M, Toniutto, P, Pasulo, L, Morelli, M, Burra, P, Miglioresi, L, Giannelli, V, Paolo, D, and Leo, A

Subjects
HCV replication, mortality, transplant patients
Published
2011

28. Liver transplantation for early-stage hepatocellular carcinoma: An intention to treat analysis

Author

Dezza, M, Corno, V, Lucianetti, A, Zambelli, M, Guizzetti, M, Pinelli, D, Sonzogni, A, Gaffuri, G, Vigano, R, Pasulo, L, Di Giorgio, M, Luca, M, Colpani, M, Verga, G, Fagiuoli, S, Colledan, M, Dezza MC, Corno V, Lucianetti A, Zambelli M, Guizzetti M, Pinelli D, Sonzogni A, Gaffuri G, Vigano R, Pasulo L, Di Giorgio M, Luca MG, Colpani M, Verga G, Fagiuoli S, Colledan M, Dezza, M, Corno, V, Lucianetti, A, Zambelli, M, Guizzetti, M, Pinelli, D, Sonzogni, A, Gaffuri, G, Vigano, R, Pasulo, L, Di Giorgio, M, Luca, M, Colpani, M, Verga, G, Fagiuoli, S, Colledan, M, Dezza MC, Corno V, Lucianetti A, Zambelli M, Guizzetti M, Pinelli D, Sonzogni A, Gaffuri G, Vigano R, Pasulo L, Di Giorgio M, Luca MG, Colpani M, Verga G, Fagiuoli S, and Colledan M

Published
2007

29. Centrilobular necro-inflammatory changes in HCV-negative liver transplant recipients respond to treatment with steroids and mycophenolate mofetil

Author

Vigano, R, Fagiuoli, S, Sonzogni, A, Pasulo, L, Gaffiari, G, Colledan, M, Strazzabosco, M, Vigano R, Fagiuoli S, Sonzogni A, Pasulo L, Gaffiari G, Colledan M, Strazzabosco M, Vigano, R, Fagiuoli, S, Sonzogni, A, Pasulo, L, Gaffiari, G, Colledan, M, Strazzabosco, M, Vigano R, Fagiuoli S, Sonzogni A, Pasulo L, Gaffiari G, Colledan M, and Strazzabosco M

Published
2007

30. Results after liver transplantation in children and adults: Analysis of survival according to the type of graft

Author

Corno, V, Lucianetti, A, Pinelli, D, Guizzetti, M, Dezza, M, Zambelli, M, Tagliabue, F, Gaffuri, G, Melzi, M, Candusso, M, Stroppa, P, Bravi, M, Verga, G, Vigano, R, Colpani, M, Luca, M, Fagitioli, S, Torre, G, Colledan, M, Corno V, Lucianetti A, Pinelli D, Guizzetti M, Dezza MC, Zambelli M, Tagliabue F, Gaffuri G, Melzi ML, Candusso M, Stroppa P, Bravi M, Verga G, Vigano R, Colpani M, Luca MG, Fagitioli S, Torre G, Colledan M, Corno, V, Lucianetti, A, Pinelli, D, Guizzetti, M, Dezza, M, Zambelli, M, Tagliabue, F, Gaffuri, G, Melzi, M, Candusso, M, Stroppa, P, Bravi, M, Verga, G, Vigano, R, Colpani, M, Luca, M, Fagitioli, S, Torre, G, Colledan, M, Corno V, Lucianetti A, Pinelli D, Guizzetti M, Dezza MC, Zambelli M, Tagliabue F, Gaffuri G, Melzi ML, Candusso M, Stroppa P, Bravi M, Verga G, Vigano R, Colpani M, Luca MG, Fagitioli S, Torre G, and Colledan M

Published
2007

31. FIBROSIS PROGRESSION AFTER ANTIVIRAL TREATMENT (AT) FOR HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION

Author

De Martin E, Masier A, Senzolo M, Boninsegna S, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, Donato FC, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, Russo FP, Cillo U, Fagiuoli S, Burra P, De Martin, E, Masier, A, Senzolo, M, Boninsegna, S, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Russo, F, Cillo, U, Fagiuoli, S, and Burra, P

Subjects
Transplantation, Hepatology, Gastroenterology, Surgery
Published
2009

32. GENOTYPE 2 AND 3 RECCURENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EXCELLENT RESULTS WITH SUBOPTIMAL DOSES OF ANTIVIRAL THERAPY

Author

Vigano R, Ponziani FR, Belli LS, Vangeli M, Pinzello G, Gasbarrini A, Pasulo L, De Martin E, Burra P, Pompili M, Colledan M, Cillo U, Fagiuoli S, Vigano, R, Ponziani, F, Belli, L, Vangeli, M, Pinzello, G, Gasbarrini, A, Pasulo, L, De Martin, E, Burra, R, Pompili, M, Colledan, M, Cillo, U, Fagiuoli, S, and Burra, P

Subjects
Hepatology, Gastroenterology
Published
2009

33. The Benefit of Antiviral Therapy On Fibrosis Progression Due To Hcv Recurrence After Liver Transplantation (lt): An Italian Multicenter Study

Author

De Martin E, Senzolo M, Ponziani F, Vigano R, Belli LS, Pinzello G, Colledan M, Donato MF, Di Paolo D, Angelico M, Rendina M, Pompili M, Merli M, Villa E, Russo FP, Boninsegna S, Cillo U, Gasbarrini A, Toniutto P, Fagiuoli S, Burra P, De Martin, E, Senzolo, M, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, M, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Merli, M, Villa, E, Russo, F, Boninsegna, S, Cillo, U, Gasbarrini, A, Toniutto, P, Fagiuoli, S, and Burra, P

Subjects
Hepatology, Gastroenterology
Published
2009

34. GENOTYPE 2 AND 3 RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EXCELLENT RESULTS WITH SUBOPTIMAL DOSES OF ANTIVIRAL THERAPY

Author

Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, De Martin E, Burra P, Boninsegna S, Donato F, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, Fagiuoli S, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, De Martin, E, Burra, P, Boninsegna, S, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, and Fagiuoli, S

Subjects
Transplantation, Hepatology, Gastroenterology, Surgery
Published
2009

44. Fibrosis Progression in Non Responders to Antiviral Treatment (AT) in HCV Recurrence Following Liver Transplantation (LT): An Italian Multicenter Retrospective Study

Author

DE MARTIN, Eleonora, Senzolo, Marco, Francesca, P. R., Pasulo, L., Vigano, R., Belli, L., Donato, F., Angelico, M., Paolo, D. D., Rendina, M., Miglioresi, L., Grazi, G. L., Morelli, M., Toniutto, P., Merli, M., Giannelli, V., Castellaneta, N. M., Marino, M., Iemmolo, R. M., Gerunda, G. E., Villa, E., Gasbarrini, A., Fagiuoli, S., and Burra, Patrizia

Published
2010

46. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer

Author

Mangili G. 1, Picchio M. 2, Sironi S. 3, 4, Vigano R. 1, Rabaiotti E. 1, Bornaghi D. 1, Bettinardi V. 2, Crivellaro C. 3, Messa C. 3, 5, 6, and Fazio F. 2

Subjects
Single-session staging procedure, PET/CT, FDG, Ovarian cancer, Clinical management
Abstract

Purpose The aims of this study were to compare CT with PET/CT results in patients with suspected ovarian cancer recurrence and to assess the impact of the PET/CT findings on their clinical management. Methods Thirty-two consecutive patients with suspected ovarian cancer recurrence were retrospectively included in the study. Abdominal contrast-enhanced CT and PET/CT with [18F]FDG, in addition to conventional follow-up, were performed in all 32 patients. After the comparison between CT and PET/CT results, based on clinical reports, changes in the clinical management of patients (intermodality changes) due to PET/CT information were analysed. Results Twenty of the 32 patients were positive at CT (62.5%) versus 29 (90.6%) at PET/CT. Intermodality changes in management, i.e. use of a different treatment modality, after PET/CT examination were indicated in 14/32 (44%) patients. In particular, before PET/CT study, the planned management was as follows: wait-and-see in 7/32 (22%), further instrumental examinations in 4/32 (12%), chemotherapy in 10/32 (31%), diagnostic surgical treatment in 6/32 (19%) and surgical treatment in the remaining 5/32 (16%). After PET/CT study, wait-and-see was indicated in 1/32 (3%), further instrumental examinations in 7/32 (22%), chemotherapy in 16/32 (50%), diagnostic surgical treatment in 2/32 (6%) and surgical treatment in the remaining 6/32 (19%). Conclusion Integrated PET/CT could detect tumour relapse in a higher percentage of patients than could CT. A change in the clinical management was observed in 44% of cases when PET/CT information was added to conventional follow-up findings.

Published
2007

50. Clinicopathologic analysis of 370 cases of vulvar intraepithelial neoplasia - Italian Study Group on vulvar disease

Author

Agarossi A, Atlante G, Baldi L, Barbero M, Bennici S, Bianchi A, Borgno G, Bracco GL, Bruno MT, Buscemi A, Canni M, Carinelli S, Carli P, Cattaneo A, Cavagnini A, Conti M, Costa S, DeCecco L, DeMarco A, DeSanctis R, Dragoni L, Falchetti M, Ferrari A, Gerbaldo D, Ghiringhello B, Guida G, Leone M, Maresi MP, Mariani L, Martinelli G, Matarazzo C, Micheletti L, Minissale L, Muggiasca ML, Nicolaci P, Nuciforo G, Palumbo G, Prati E, Preti M, Pulvirenti G, Rampinelli F, Sciarretta F, Sideri M, Sonni L, Taddei GL, Vendra C, Virgili A, Vigano R, Valentino MCZ, ORIGONI , MASSIMO, Agarossi, A, Atlante, G, Baldi, L, Barbero, M, Bennici, S, Bianchi, A, Borgno, G, Bracco, Gl, Bruno, Mt, Buscemi, A, Canni, M, Carinelli, S, Carli, P, Cattaneo, A, Cavagnini, A, Conti, M, Costa, S, Dececco, L, Demarco, A, Desanctis, R, Dragoni, L, Falchetti, M, Ferrari, A, Gerbaldo, D, Ghiringhello, B, Guida, G, Leone, M, Maresi, Mp, Mariani, L, Martinelli, G, Matarazzo, C, Micheletti, L, Minissale, L, Muggiasca, Ml, Nicolaci, P, Nuciforo, G, Origoni, Massimo, Palumbo, G, Prati, E, Preti, M, Pulvirenti, G, Rampinelli, F, Sciarretta, F, Sideri, M, Sonni, L, Taddei, Gl, Vendra, C, Virgili, A, Vigano, R, and Valentino, Mcz

Abstract

OBJECTIVE: To investigate epidemiologic, clinical and pathologic aspects of various grades of vulvar intraepithelial neoplasia (VIN). STUDY DESIGN: A retrospective, multicenter study of 370 cases of vulvar intraepithelial neoplasia (VIN) wits performed by the Italian Study Group on Vulvar Disease. RESULTS: Of the 370 cases, 148 were VIN 1 (40.0%), 53 were VIN 2 (14.3%), and 169 were VIN 3 (45.7%). The mean age of the patients was 52.6 years. During the study period an increase in the rate of human papillomavirus-associated VIN was observed. In addition, while VIN 1 and 2 were associated mostly with squamous cell hyperplasia, VIN 3 was almost equally associated with lichen sclerosus and squamous cell hyperplasia; the difference was statistically significant. Intraepithelial or invasive squamous neoplasia of the lower genital tract was associated in 22% of the cases (82/370). CONCLUSION The results of the investigation, although not allowing firm conclusions due to the retrospective and multicentered nature of the study, demonstrate the extreme heterogeneity of VIN lesions.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results